Proactive Investors - Run By Investors For Investors

Sareum secures funding for drug programme

The company has raised £850,000 before expenses, which will be used to develop potential treatments for cancer and autoimmune diseases
researcher filling testtube
“We believe we have strong candidates with optimised profiles in these areas and are focused on advancing these into preclinical development towards clinical trials,” said chief executive, Dr Tim Mitchell.

Sareum Holdings Plc (LON:SAR) said it had completed a share placing that has raised £850,000.

The proceeds will be used for working capital purposes and to fund the development of its TYK2/JAK1 targets, which are being developed to treat autoimmune disease and cancer.

READ: Sareum selects potential anti-cancer molecule for further development

“We believe we have strong candidates with optimised profiles in these areas and are focused on advancing these into preclinical development towards clinical trials,” said chief executive, Dr Tim Mitchell.

“These new funds, added to our current cash, will enable us to advance these studies and build up the evidence required to facilitate a licensing agreement at an optimal value."

The stock, which closed Thursday at 0.78p, was sold in placing for 0.65p a share.

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 22 2019

Related Articles

cannabis
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use